Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study - Top-Institutions - MDSpire

Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study

  • By

  • Lulu Zhuang

  • Xiaoyan Yin

  • Xiaoli Liu

  • Defeng Liu

  • Zhonghui Wei

  • Yu Chen

  • Kaikai Zhao

  • Yankang Li

  • Jinming Yu

  • Xiangjiao Meng

  • February 4, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Neuro-Oncology
    • Clinical Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Thoracic Oncology
    • Neuro-Oncology
    • Molecular Oncology

  • #3

    Fudan University Shanghai Cancer Center
    Fudan University Shanghai Cancer Center

    Shanghai, Shanghai

    Key Differentiators

    • Thoracic Oncology
    • Clinical Pharmacology
    • Translational Research

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Oncology
    • Neuro-Oncology
    • Clinical Trials

  • #5

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Tokyo

    Key Differentiators

    • Thoracic Oncology
    • Neuro-Oncology
    • Clinical Research

Original Source(s)

Efficacy and safety of aumolertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis: a single‑center retrospective study

  • by Lulu Zhuang, Xiaoyan Yin, Xiaoli Liu, Defeng Liu, Zhonghui Wei, Yu Chen, Kaikai Zhao, Yankang Li, Jinming Yu, Xiangjiao Meng

  • February 4, 2025

Related Content

Solid-variant primary pulmonary adenoid cystic carcinoma with pleural metastasis and malignant pleural effusion: a rare case report

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy